211 related articles for article (PubMed ID: 34085764)
1. Bayesian single-arm phase II trial designs with time-to-event endpoints.
Wu J; Pan H; Hsu CW
Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
3. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
4. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
Shi H; Yin G
Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
[TBL] [Abstract][Full Text] [Related]
5. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.
Zhao L; Taylor JM; Schuetze SM
Stat Med; 2012 Jul; 31(17):1804-20. PubMed ID: 22359354
[TBL] [Abstract][Full Text] [Related]
6. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
Cotterill A; Whitehead J
Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
[TBL] [Abstract][Full Text] [Related]
7. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
Xu T; Shi H; Lin R
Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
[TBL] [Abstract][Full Text] [Related]
8. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
9. Bayesian designs with frequentist and Bayesian error rate considerations.
Wang YG; Leung DH; Li M; Tan SB
Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
[TBL] [Abstract][Full Text] [Related]
10. Two-stage phase II survival trial design.
Wu J; Chen L; Wei J; Weiss H; Chauhan A
Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
[TBL] [Abstract][Full Text] [Related]
11. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
12. Bayesian designs and the control of frequentist characteristics: a practical solution.
Ventz S; Trippa L
Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
[TBL] [Abstract][Full Text] [Related]
13. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
Kaizer A; Zabor E; Nie L; Hobbs B
PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
15. Bayesian two-stage design for phase II oncology trials with binary endpoint.
Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
[TBL] [Abstract][Full Text] [Related]
16. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
17. Bayesian two-stage designs for phase II clinical trials.
Tan SB; Machin D
Stat Med; 2002 Jul; 21(14):1991-2012. PubMed ID: 12111883
[TBL] [Abstract][Full Text] [Related]
18. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
19. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
20. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]